ReviewThe AAPS journal2006
Symbiotic relationship of pharmacogenetics and drugs of abuse.
Review in The AAPS journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.Drug and alcohol dependence · 2015Trial
- The Neuroscience of Drug Reward and Addiction.Physiological reviews · 2019Review
- Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders.Frontiers in psychiatry · 2019Review
- Pathways to precision medicine in smoking cessation treatments.Neuroscience letters · 2018Review
- Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018Review
- Re-defininG AddiC(CH3)Tion: genomics and epigenomics on substance use disorders.Molecular genetics & genomic medicine · 2014Article
- Addiction science: Uncovering neurobiological complexity.Neuropharmacology · 2014Review
- Genomics and personalized medicine:Journal of food and drug analysis · 2013Article
- Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success.The American journal of psychiatry · 2012Article
- Ethical concerns related to developing pharmacogenomic treatment strategies for addiction.Addiction science & clinical practice · 2011Article
- Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.Forensic science, medicine, and pathology · 2011Review
- Addiction as a systems failure: focus on adolescence and smoking.Journal of the American Academy of Child and Adolescent Psychiatry · 2011Review
- Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment.Addiction science & clinical practice · 2010Review
- Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.Biochemical pharmacology · 2009Article
- Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment.The pharmacogenomics journal · 2008Article
- Indolealkylamines: biotransformations and potential drug-drug interactions.The AAPS journal · 2008Review
- Genetics and smoking cessation improving outcomes in smokers at risk.American journal of preventive medicine · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pharmacogenetics/pharmacogenomics is the study of how genetic variation affects pharmacology, the use of drugs to treat disease. When drug responses are predicted in advance, it is easier to tailor medications to different diseases and individuals. Pharmacogenetics provides the tools required to identify genetic predictors of probable drug response, drug efficacy, and drug-induced adverse events-identifications that would ideally precede treatment decisions. Drug abuse and addiction genetic data have advanced the field of pharmacogenetics in general. Although major findings have emerged, pharmacotherapy remains hindered by issues such as adverse events, time lag to drug efficacy, and heterogeneity of the disorders being treated. The sequencing of the human genome and high-throughput technologies are enabling pharmacogenetics to have greater influence on treatment approaches. This review highlights key studies and identifies important genes in drug abuse pharmacogenetics that provide a basis for better diagnosis and treatment of drug abuse disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.